Latest Development in B Cell Malignancies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 12476
Special Issue Editors
Interests: chronic lymphocytic leukemia; cancer genetics; tumor microenvironment; molecular biology
Special Issues, Collections and Topics in MDPI journals
Interests: CLL; B cell lymphoma; tumor biology; signaling pathway; genetic alterations
Special Issue Information
Dear Colleagues,
B cell malignancies are heterogeneous in terms of genetic alterations, biological mechanisms sustaining tumor cells and, consequently, disease outcome. Over the past few years, growing interest in critical pathways has led to the discovery and design of treatment options with groundbreaking results and changes in the clinical practice, such as ibrutinib and its derivatives, or venetoclax. It is now clear that both intrinsic features of malignant B cells and the microenvironment play a pivotal role in driving and sustaining malignant B cell evolution, and that this is a two-way relationship, where tumor cells shape the bystander populations toward tolerance and support. The current challenge is to dissect and deeply characterize the biology of B cell malignancies to understand the most significant mechanism behind B cell transformation and disease progression and find targetable weak spots. This Special Issue welcomes reviews, as well as original research articles.
Dr. Francesca Arruga
Dr. Federico Pozzo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- B cell malignancies
- target therapy
- microenvironment
- genetic lesions